Drug & intervention

darolutamide

RxCUI 2180325

Clinical trials55
Recruiting25
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)NCT07723248 · 2026-08-03
RECRUITING
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT TreatmentNCT07538843 · 2026-07-31
RECRUITING
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate CancerNCT07027124 · 2026-05-21
RECRUITING
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04
RECRUITING
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.NCT07450599 · 2026-04-27
RECRUITING
Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseNCT07142551 · 2026-03-09
RECRUITING
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT07190300 · 2026-01-13
RECRUITING
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07244341 · 2025-12-03
RECRUITING
Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScoreNCT07617272 · 2025-11-09
RECRUITING
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerNCT07140900 · 2025-10-07
RECRUITING
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCNCT07016399 · 2025-09-09
RECRUITING
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology ClinicsNCT07406282 · 2025-07-22
RECRUITING
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseNCT06625970 · 2025-04-10
RECRUITING
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.NCT06724159 · 2024-12-13
RECRUITING
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06401980 · 2024-10-22
RECRUITING
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate CancerNCT06631521 · 2024-10-22
RECRUITING
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialNCT06378866 · 2024-06-03
RECRUITING
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate CancerNCT06575257 · 2024-05-01
RECRUITING
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerNCT06190899 · 2024-01-01
RECRUITING
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular TracersNCT06282588 · 2023-12-13
RECRUITING
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPCNCT05762536 · 2023-11-29
RECRUITING
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerNCT06173362 · 2023-11-09
RECRUITING
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerNCT05818683 · 2023-04-26
RECRUITING
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)NCT05519449 · 2022-09-15
RECRUITING
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerNCT03903835 · 2019-02-01
RECRUITING
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNCT07852195 · 2027-01-06
NOT_YET_RECRUITING
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.NCT06660862 · 2026-11-01
NOT_YET_RECRUITING
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)NCT07711002 · 2026-10-01
NOT_YET_RECRUITING
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.NCT07730151 · 2026-08-01
NOT_YET_RECRUITING
Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate CancerNCT07476677 · 2026-04-01
NOT_YET_RECRUITING
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)NCT06463457 · 2024-12-13
ACTIVE_NOT_RECRUITING
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerNCT04176081 · 2024-07-02
NOT_YET_RECRUITING
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET StudyNCT06430411 · 2024-05-31
NOT_YET_RECRUITING
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentNCT05999968 · 2024-01-12
TERMINATED
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21
ACTIVE_NOT_RECRUITING
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.NCT05938270 · 2023-09-21
COMPLETED
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPCNCT05771896 · 2023-09-01
WITHDRAWN
Neo-DAB: Darolutamide and Abemaciclib in Prostate CancerNCT05617885 · 2023-08-09
COMPLETED
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerNCT05367440 · 2022-06-02
ACTIVE_NOT_RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06
ACTIVE_NOT_RECRUITING

Conditions being studied

Prostate Cancer21Metastatic Castration-Resistant Prostate Cancer7Metastatic Prostate Cancer5Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)4Castrate Resistant Prostate Cancer3Metastatic Hormone-sensitive Prostate Cancer3Prostate Cancer Metastatic3Breast Cancer Female2Hormone Sensitive Prostate Cancer2Non-metastatic Prostate Cancer2Oligometastasis2Prostate Cancer (Adenocarcinoma)2Prostatic Neoplasms2Stage IV Prostate Cancer AJCC v82Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Advanced Prostate Adenocarcinoma1Advanced Prostate Cancer1Advanced Prostate Carcinoma1Advanced Solid Tumors1Anatomic Stage II Breast Cancer AJCC v81

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.